We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical.

Type
Public
HQ
Hamburg, DE
Founded
1993
Evotec was founded in 1993 and is headquartered in Hamburg, DE

Key People at Evotec

Werner Lanthaler

Werner Lanthaler

CEO
Mario Polywka

Mario Polywka

COO
Cord Dohrmann

Cord Dohrmann

CSO
Colin Bond

Colin Bond

CFO

Evotec Locations

Hamburg, DE
Branford, US
Princeton, US
Göttingen, DE
Toulouse, FR
Planegg, DE
Manchester, GB
South San Francisco, US
Milton, GB

Evotec Metrics

Evotec Summary

Market capitalization

€822 M

Closing share price

€6.18
Evotec's latest market capitalization is €822 M.

Evotec Market Value History

Evotec Company Life

You may also be interested in